Abstract |
Ten children received amikacin twice daily and 13 were treated using the single daily protocol. All had fever and neutropenia on admission, and received a total daily dose of 20 mg/kg when included in the study. Individual pharmacokinetic parameters were calculated using a one-compartment model for two blood amikacin samples. The mean (+/- SD) of elimination half-life (h), amikacin clearance (l/h/kg), volume of distribution (l/kg), peak concentration (microgram/ml) and trough concentration (microgram/ml) were: 2.51 (0.74) and 2.85 (0.32) h; 0.26 (0.16) and 0.115 (0.02) l/h/kg; 0.74 (0.44) and 0.47 (0.11) l/kg; 19.1 (12.3) and 42.6 (12.6) micrograms/ml; 0.85 (0.74) and 0.18 (0.24) microgram/ml with twice and single daily dosage schedules, respectively. A single daily dose of amikacin had a significantly longer elimination half-life, lower clearance, higher peak concentration and lower trough concentration in comparison to the twice-daily schedule. The use of amikacin 20 mg/kg daily delivered in a single daily dose is recommended for immunocompromised pediatric patients with fever and neutropenia, in spite of the measured pharmacokinetic differences.
|
Authors | N Krivoy, S Postovsky, R Elhasid, M W Ben Arush |
Journal | Infection
(Infection)
1998 Nov-Dec
Vol. 26
Issue 6
Pg. 396-8
ISSN: 0300-8126 [Print] Germany |
PMID | 9861567
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Amikacin
|
Topics |
- Adolescent
- Amikacin
(administration & dosage, blood, pharmacokinetics)
- Anti-Bacterial Agents
(administration & dosage, blood, pharmacokinetics)
- Bacterial Infections
(drug therapy)
- Child
- Child, Preschool
- Drug Administration Schedule
- Female
- Fever of Unknown Origin
(complications)
- Humans
- Immunocompromised Host
- Infant
- Male
- Neoplasms
(complications)
- Neutropenia
(complications)
|